Izrael - héber - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Izrael - héber - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Izrael - héber - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Izrael - héber - Ministry of Health

cartiheal (2009) ltd. - רופא - agili-c implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and/or osteochondral defects. it is indicated for cartilage and/or bone repair. the implant serves as a scaffold for cellular and matrix ingrowth. the agili-c implant is expected to biodegrade within 6 – 12 months.

Izrael - héber - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

Izrael - héber - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

Izrael - héber - Ministry of Health

abic marketing ltd, israel - modafinil - קפליות - modafinil 100 mg - modafinil

Izrael - héber - Ministry of Health

abic marketing ltd, israel - modafinil - קפליות - modafinil 100 mg - modafinil

Izrael - héber - Ministry of Health

rafa laboratories ltd - terbinafine hydrochloride - קרם - terbinafine hydrochloride 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g.t.rubrum, t. mentagrophytes, t. verrucosu, t. violaceum), microsporum canis and epidemophyton floccosum. yeast infections of the skin, principally those caused by the genus candida (e.g. candida albicans). pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).

Izrael - héber - Ministry of Health

rafa laboratories ltd - terbinafine hydrochloride - קרם - terbinafine hydrochloride 1 % - terbinafine - terbinafine - fungal infections of the skin caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidemophyton floccosum. yeast infections of the skin, principally those caused by the genus candida (e.g. candida albicans). pityriasis (tinea versicolor due to pityrosporum orbiculare (also known as malassezia furfur).